Related Experiment Video
Updated: Oct 31, 2025
09:19
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
2.0K
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Yvonne Andersson1, Karianne G Fleten1, Torveig W Abrahamsen1
1Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway.
Cancers
|July 2, 2021
Summary
Pseudomyxoma peritonei (PMP) is a rare cancer driven by angiogenesis. Anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) show promise in inhibiting PMP tumor growth, offering new therapeutic avenues.
Area of Science:
- Oncology
- Cancer Biology
- Angiogenesis Research
Background:
- Pseudomyxoma peritonei (PMP) is a rare malignancy with limited treatment options for unresectable or recurrent cases.
- Angiogenesis, the formation of new blood vessels, is increasingly recognized as a critical factor in cancer progression.
- Anti-angiogenic therapies are being investigated as a potential treatment strategy for PMP.
Purpose of the Study:
- To investigate the role of angiogenesis in PMP.
- To evaluate the efficacy of anti-angiogenic drugs in preclinical PMP models.
Main Methods:
- Analysis of microvessel density and pro-angiogenic factors in PMP patient samples.
- Assessment of human umbilical cord vascular endothelial cell (HUVEC) proliferation in response to PMP samples.
- Evaluation of tumor growth inhibition by VEGF pathway inhibitors (bevacizumab, aflibercept) in patient-derived xenograft models.
Main Results:
- PMP tumor tissues exhibit high vascularization and express key pro-angiogenic factors, notably related to VEGF signaling.
- PMP samples stimulated HUVEC proliferation, which was inhibited by bevacizumab.
- Bevacizumab and aflibercept demonstrated tumor growth inhibition in PMP xenograft models.
Conclusions:
- Angiogenesis is a significant driver of PMP progression.
- VEGF pathway inhibitors show preclinical efficacy, supporting their continued investigation for PMP treatment.
- Anti-angiogenic therapy represents a promising novel treatment strategy for patients with limited options.
